Ultra-rapid lispro (URLi; Lyumjev) has an improved pharmacokinetic profile for exercise as compared to Humalog and results in less exercise-associated hypoglycemia in adults with type 1 diabetes on open-loop continuous subcutaneous insulin infusion (CSII).

Read full text Summarise with VIRAT
Authors: Jennifer K. Leohr, Alexander Abitbol, Lauren V. Turner, Elizabeth Smith LaBell, ARITRA GHOSH, David E. Coutant, Michael Charles Riddell
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective To compare the glycemic response and pharmacokinetics (PK) of Lyumjev versus Humalog during manual basal rate reductions (BRR) before exercise with conventional continuous subcutaneous insulin infusion (CSII) in active adults with type 1 diabetes. Research Design and Methods This was a randomized, double-blind, 4-period, crossover-controlled trial. Exercise (60 minutes walking at 45-55% VO2max) was performed 4 hours after a standardized meal, with either a 50% (-60 minutes) or 100% (-15 minutes) BRR before exercise using Lyumjev or Humalog. The primary endpoint was the change in glucose during exercise, and insulin lispro PK was the secondary endpoint. Results Twenty-five participants (mean ± SD, age 36.7 ± 10.3 yr; HbA1c 50.4 ± 8.5 mmol/mol [6.76 ± 0.8%]; 48% female) completed the study. Lyumjev significantly attenuated the reduction in glucose level compared to Humalog during both the 50% BRR (-26.8 ± 37 vs -39.0 ± 39 mg/dL, p

Fields of Study & Subjects

Diabetes Management and Research Diabetes Treatment and Management Diabetes Management and Education

Publication details

Publication date
26 March 2026
Language
EN